Risk factor
Low price volatility
Profitability factor
Overvalued vs peers
About
Tecan Group AG, established in 1980 and headquartered in Männedorf, Switzerland, specializes in providing cutting-edge laboratory instruments and holistic solutions. The company caters to a broad spectrum of clients, including pharmaceutical and biotechnology corporations, university research departments, and forensic and diagnostic laboratories. Its operations are structured into two principal segments: Life Sciences Business and Partnering Business. Tecan's extensive product portfolio features automated liquid handling systems, microplate readers and washers, various consumables, reagents for Next-Generation Sequencing (NGS), immunoassays, microbodies, and specialized software. Key proprietary solutions include Tecan Laberwax for automated workflows and Resolvex, an intelligent sample preparation system applicable across diverse fields such as genomics, synthetic biology, drug discovery, analytical chemistry, cell biology, protein science, applied markets, and ELISA. Additionally, Tecan develops and manufactures crucial components—like precision pumps, valves, robotic arms, and developer software—for other laboratory instrument producers serving life science research, diagnostics, and various industrial applications. Its advanced platform-based automation solutions include Synergence, Freedom EVO, and Fluent instruments. The company's global footprint spans Switzerland, other European nations, North America, Asia, and other international markets.
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA, tr
Target Price
The average target price of TECN.SW is 217 and suggests 7.81% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to